166 related articles for article (PubMed ID: 28042030)
1. Ectopic expression of the CDK inhibitor p21
Kurayoshi K; Shiromoto A; Ozono E; Iwanaga R; Bradford AP; Araki K; Ohtani K
Biochem Biophys Res Commun; 2017 Jan; 483(1):107-114. PubMed ID: 28042030
[TBL] [Abstract][Full Text] [Related]
2. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs.
Kurayoshi K; Ozono E; Iwanaga R; Bradford AP; Komori H; Ohtani K
Biochem Biophys Res Commun; 2014 Jul; 450(1):240-6. PubMed ID: 24893334
[TBL] [Abstract][Full Text] [Related]
3. C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
Elliott MJ; Stilwell A; Dong YB; Yang HL; Wong SL; Wrightson WR; Martin RC; McMasters KM
Cancer Gene Ther; 2002 May; 9(5):453-63. PubMed ID: 11961668
[TBL] [Abstract][Full Text] [Related]
4. The phosphatidyl inositol 3 kinase pathway does not suppress activation of the ARF and BIM genes by deregulated E2F1 activity.
Kurayoshi K; Okuno J; Ozono E; Iwanaga R; Bradford AP; Kugawa K; Araki K; Ohtani K
Biochem Biophys Res Commun; 2017 Jan; 482(4):784-790. PubMed ID: 27888102
[TBL] [Abstract][Full Text] [Related]
5. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.
Nakajima R; Zhao L; Zhou Y; Shirasawa M; Uchida A; Murakawa H; Fikriyanti M; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833320
[TBL] [Abstract][Full Text] [Related]
6. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F.
Nakajima R; Deguchi R; Komori H; Zhao L; Zhou Y; Shirasawa M; Angelina A; Goto Y; Tohjo F; Nakahashi K; Nakata K; Iwanaga R; Bradford AP; Araki K; Warita T; Ohtani K
Biochem Biophys Res Commun; 2023 Jun; 663():154-162. PubMed ID: 37141667
[TBL] [Abstract][Full Text] [Related]
7. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.
Ofir M; Hacohen D; Ginsberg D
Mol Cancer Res; 2011 Apr; 9(4):440-7. PubMed ID: 21454377
[TBL] [Abstract][Full Text] [Related]
8. Functional interplay between p53 and E2F through co-activator p300.
Lee CW; Sørensen TS; Shikama N; La Thangue NB
Oncogene; 1998 May; 16(21):2695-710. PubMed ID: 9652736
[TBL] [Abstract][Full Text] [Related]
9. Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.
Aslanian A; Iaquinta PJ; Verona R; Lees JA
Genes Dev; 2004 Jun; 18(12):1413-22. PubMed ID: 15175242
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts.
Kitamura H; Ozono E; Iwanaga R; Bradford AP; Okuno J; Shimizu E; Kurayoshi K; Kugawa K; Toh H; Ohtani K
Genes Cells; 2015 Sep; 20(9):739-57. PubMed ID: 26201719
[TBL] [Abstract][Full Text] [Related]
11. RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.
Feldstein O; Ben-Hamo R; Bashari D; Efroni S; Ginsberg D
Mol Cancer Res; 2012 Sep; 10(9):1169-77. PubMed ID: 22798430
[TBL] [Abstract][Full Text] [Related]
12. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway.
Russell JL; Weaks RL; Berton TR; Johnson DG
Oncogene; 2006 Feb; 25(6):867-76. PubMed ID: 16205640
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts.
Ozono E; Komori H; Iwanaga R; Tanaka T; Sakae T; Kitamura H; Yamaoka S; Ohtani K
Genes Cells; 2012 Aug; 17(8):660-72. PubMed ID: 22702391
[TBL] [Abstract][Full Text] [Related]
14. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
15. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
Hiyama H; Iavarone A; LaBaer J; Reeves SA
Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry.
Dai Y; Hamm TE; Dent P; Grant S
Cell Cycle; 2006 Feb; 5(4):437-46. PubMed ID: 16479154
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F.
Hiyama H; Iavarone A; Reeves SA
Oncogene; 1998 Mar; 16(12):1513-23. PubMed ID: 9569018
[TBL] [Abstract][Full Text] [Related]
18. E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity.
Ozono E; Komori H; Iwanaga R; Ikeda MA; Iseki S; Ohtani K
Genes Cells; 2009 Jan; 14(1):89-99. PubMed ID: 19077036
[TBL] [Abstract][Full Text] [Related]
19. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.
Cascallo M; Alonso MM; Rojas JJ; Perez-Gimenez A; Fueyo J; Alemany R
Mol Ther; 2007 Sep; 15(9):1607-15. PubMed ID: 17579575
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation.
Itoshima T; Fujiwara T; Waku T; Shao J; Kataoka M; Yarbrough WG; Liu TJ; Roth JA; Tanaka N; Kodama M
Clin Cancer Res; 2000 Jul; 6(7):2851-9. PubMed ID: 10914734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
